Recombinant Human BMP-9 Instruction

General description

Bone Morphogenetic Protein 9 is the most potent endogenous inducer of osteogenic differentiation, acting through the ALK1 receptor to drive bone formation and vascular quiescence. It uniquely regulates both skeletal and vascular biology through distinct signaling mechanisms. Recombinant Human BMP-9 Protein (Y10801) is expressed from mammalian cells. It contains AA Gln 320 - Arg 429 (Accession # Q9UK05), and is widely used in advanced cell culture, vascular biology, and orthopedic research.

Application

· Potent Osteogenic Differentiation — Drives rapid and robust bone matrix formation from MSCs and osteoprogenitors.

· Vascular Endothelial Quiescence — Maintains blood vessel stability through ALK1-dependent signaling.

· Hereditary Hemorrhagic Telangiectasia Research — Models ALK1 mutation-driven vascular dysplasia.

· Liver Biology and Hepatic Differentiation — Supports hepatocyte function and liver progenitor maintenance.

· Serum-Free Culture Systems — Suitable for chemically defined and xeno-free cell culture media.

Product Specifications

Stability and Reconstitution

· 36 months at -20°C to -80°C in lyophilized state;

· 6 months at -20°C to -80°C under sterile conditions after reconstitution;

· 7-10 days at 2°C to 8°C under sterile conditions after reconstitution;

· Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

· It is recommended to redissolve in 4mM HCL.

Backgroud

Bone Morphogenetic Protein 9, also known as BMP-9 or GDF-2, is a member of the TGF-β superfamily that was originally identified as a circulating factor produced by the liver. BMP-9 is unique among BMPs in its high-affinity binding to the type I receptor ALK1 (ACVRL1), which is predominantly expressed on vascular endothelial cells, and its requirement for the co-receptor endoglin for optimal signaling. Through ALK1, BMP-9 maintains vascular quiescence and inhibits endothelial cell proliferation and migration, with genetic mutations in ALK1 or endoglin causing hereditary hemorrhagic telangiectasia (HHT), a vascular dysplasia characterized by arteriovenous malformations. In skeletal biology, BMP-9 is considered the most potent endogenous osteogenic factor, surpassing BMP-2 and BMP-7 in inducing osteogenic differentiation of mesenchymal stem cells through SMAD1/5/8-dependent activation of RUNX2 and Osterix. This dual role in vascular and skeletal biology makes BMP-9 particularly relevant for studying the coupling of angiogenesis and osteogenesis during bone repair. In liver biology, BMP-9 is produced by hepatocytes and regulates hepatic glucose metabolism and lipid homeostasis. EastMabBio's mammalian-expressed BMP-9 is validated for osteogenic differentiation assays, endothelial cell quiescence studies, and hepatic cell culture applications.

Q&A

Q1: What is BMP-9 mainly used for?

BMP-9 is primarily used for potent osteogenic differentiation, vascular quiescence research, HHT modeling, and liver biology studies.

Q2: Is this BMP-9 suitable for serum-free culture systems?

Yes. EastMabBio recombinant BMP-9 is compatible with serum-free, xeno-free, and chemically defined media systems.

Q3: How should recombinant BMP-9 be stored?

Lyophilized protein should be stored at -20°C or below. After reconstitution, aliquot and avoid repeated freeze-thaw cycles.

Q4: What shipping conditions are used?

Products are shipped on dry ice with validated cold-chain packaging to maintain stability during international transportation.

Q5: Do you provide QC documents?

Yes. COA, MSDS, TSE-BSE statements, endotoxin reports, bioactivity data, and additional QC documentation are available upon request.